ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Misses Estimates By $0.02 EPS

06 May 2026, 11:56 by Renee Jackson · The Cerbat Gem

ADC Therapeutics (NYSE:ADCT – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02), RTT News reports. The firm had revenue of $20.85 million for the quarter, compared to analysts’ expectations of $19.99 million. During the same period in the prior year, the business earned ($0.36) EPS.

Here are the key takeaways from ADC Therapeutics’ conference call:

We expect the LOTIS‑5 top‑line readout before the end of June; the company is currently blinded and, if positive, plans an sBLA by year‑end with potential Compendia inclusion and a regulatory approval pathway into 2027.
Q1 net product revenues were $20.0 million versus $17.4 million a year ago, driven mainly by quarter‑to‑quarter ordering variability with management saying underlying demand remains broadly stable.
On a non‑GAAP basis ADC reduced total operating expenses by 13% year‑over‑year and ended Q1 with $231 million in cash, which management says provides runway at least into 2028.
Management reiterated plans to expand ZYNLONTA into earlier DLBCL lines and indolent lymphomas—LOTIS‑7 enrollment is expected to complete in Q2 with full data by year‑end and IIT data due end‑2026 to mid‑2027—and projects potential peak U.S. revenues of $600M–$1B assuming approvals and Compendia listings.

ADC Therapeutics Stock Up 8.1%

NYSE:ADCT traded up $0.31 during midday trading on Wednesday, hitting $4.07. The company had a trading volume of 608,500 shares, compared to its average volume of 869,188. ADC Therapeutics has a 52-week low of $1.23 and a 52-week high of $4.98. The stock’s fifty day moving average price is $4.03 and its 200-day moving average price is $3.96. The company has a market capitalization of $517.03 million, a PE ratio of -3.87 and a beta of 1.83.

Insider Transactions at ADC Therapeutics

In other ADC Therapeutics news, major shareholder Redmile Group, Llc sold 2,634,506 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $3.28, for a total value of $8,641,179.68. Following the completion of the sale, the insider directly owned 12,666,731 shares of the company’s stock, valued at $41,546,877.68. The trade was a 17.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 5,880,415 shares of company stock valued at $19,641,067 in the last ninety days. 5.40% of the stock is currently owned by insiders.

Institutional Trading of ADC Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP purchased a new stake in ADC Therapeutics during the fourth quarter valued at about $43,000. AQR Capital Management LLC boosted its position in ADC Therapeutics by 42.2% during the fourth quarter. AQR Capital Management LLC now owns 206,576 shares of the company’s stock valued at $729,000 after buying an additional 61,324 shares during the period. Cantor Fitzgerald L. P. purchased a new stake in ADC Therapeutics during the fourth quarter valued at about $353,000. Jump Financial LLC boosted its position in ADC Therapeutics by 1,299.8% during the fourth quarter. Jump Financial LLC now owns 162,250 shares of the company’s stock valued at $573,000 after buying an additional 150,659 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in ADC Therapeutics by 25.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company’s stock valued at $166,000 after buying an additional 9,537 shares during the period. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Monday, April 20th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $6.00 target price on shares of ADC Therapeutics in a research report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of ADC Therapeutics in a research report on Tuesday. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Get Our Latest Research Report on ADC Therapeutics

ADC Therapeutics Company Profile

(Get Free Report)

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.